Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
Lineage Cell Therapeutics (NYSE American and TASE: LCTX) has scheduled its third quarter 2024 financial results announcement and business update for November 14, 2024, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on the same day. Investors can join via phone at (800) 715-9871 or through the company's website. A replay will be available online for 30 days and by phone until November 21, 2024, using conference ID 2238934.
Lineage Cell Therapeutics (NYSE American e TASE: LCTX) ha programmato l'annuncio dei risultati finanziari del terzo trimestre 2024 e un aggiornamento aziendale per il 14 novembre 2024, dopo la chiusura del mercato statunitense. L'azienda ospiterà una conferenza telefonica e un webcast alle 16:30 ora orientale/13:30 ora del Pacifico lo stesso giorno. Gli investitori possono partecipare telefonicamente al numero (800) 715-9871 o attraverso il sito web dell'azienda. Una registrazione sarà disponibile online per 30 giorni e telefonicamente fino al 21 novembre 2024, utilizzando l'ID conferenza 2238934.
Lineage Cell Therapeutics (NYSE American y TASE: LCTX) ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 y una actualización empresarial para el 14 de noviembre de 2024, después del cierre del mercado estadounidense. La empresa llevará a cabo una conferencia telefónica y una transmisión web a las 4:30 p.m. hora del este/1:30 p.m. hora del pacífico el mismo día. Los inversores pueden unirse por teléfono al (800) 715-9871 o a través del sitio web de la empresa. Una grabación estará disponible en línea durante 30 días y por teléfono hasta el 21 de noviembre de 2024, utilizando el ID de conferencia 2238934.
라인이지 셀 테라퓨틱스 (NYSE American 및 TASE: LCTX)는 2024년 11월 14일에 미국 시장 마감 후 2024년 3분기 재무 결과 발표 및 사업 업데이트를 예정하고 있습니다. 이날 동부 표준시 기준 오후 4시 30분/태평양 표준시 기준 오후 1시 30분에 컨퍼런스 콜과 웹캐스트를 진행합니다. 투자자는 (800) 715-9871로 전화에 참여하거나 회사 웹사이트를 통해 참여할 수 있습니다. 재생 녹음은 30일 동안 온라인에서 이용 가능하며, 2024년 11월 21일까지 전화로 이용할 수 있으며, 회의 ID 2238934를 사용해야 합니다.
Lineage Cell Therapeutics (NYSE American et TASE : LCTX) a prévu l'annonce de ses résultats financiers du troisième trimestre 2024 et une mise à jour de l'entreprise pour le 14 novembre 2024, après la clôture des marchés américains. L'entreprise organisera une conférence téléphonique et un webinaire à 16h30, heure de l'Est/13h30, heure du Pacifique, le même jour. Les investisseurs peuvent participer par téléphone au (800) 715-9871 ou via le site web de l'entreprise. Un enregistrement sera disponible en ligne pendant 30 jours et par téléphone jusqu'au 21 novembre 2024, en utilisant l'identifiant de la conférence 2238934.
Lineage Cell Therapeutics (NYSE American und TASE: LCTX) hat die Bekanntgabe seiner finanziellen Ergebnisse für das dritte Quartal 2024 und ein Unternehmensupdate für den 14. November 2024 nach Börsenschluss in den USA angesetzt. Am selben Tag wird das Unternehmen um 16:30 Uhr Eastern Time/13:30 Uhr Pacific Time eine Telefonkonferenz und ein Webcast veranstalten. Investoren können telefonisch unter (800) 715-9871 oder über die Website des Unternehmens teilnehmen. Eine Aufzeichnung wird 30 Tage lang online verfügbar sein und bis zum 21. November 2024 telefonisch zur Verfügung stehen, unter Verwendung der Konferenz-ID 2238934.
- None.
- None.
Interested parties may access the conference call on November 14, 2024, by dialing (800) 715-9871 from the
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, “off-the-shelf,” cell therapies to address unmet medical needs. Lineage’s programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient’s functional activity. Lineage’s neuroscience focused pipeline currently includes: (i) OpRegen®, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ReSonance™ (ANP1), an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed in collaboration with Eterna Therapeutics Inc. For more information, please visit www.lineagecell.com or follow the company on X/Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241107087038/en/
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963
Russo Partners – Media Relations
Nic Johnson or David Schull
(Nic.johnson@russopartnersllc.com)
(David.schull@russopartnersllc.com)
(212) 845-4242
Source: Lineage Cell Therapeutics, Inc.
FAQ
When will Lineage Cell Therapeutics (LCTX) release Q3 2024 earnings?
How can I access LCTX's Q3 2024 earnings call?